Are there still opportunities in China and Asia for US biopharmas?

Seminar | October.19.2022 | 3pm - 5pm (Central Standard Time)

Orrick New York

China is the second largest pharmaceutical market in the world, growing to $205bn by 2026. With an increasing focus on innovation and early access, many US biopharmas have found that an anchor in China supports accelerated clinical development and creates incremental value via either through equity investments, direct entry or joint venture to access the Chinese and Asian markets, or milestones and anticipated royalties in the case of licensing. Do these opportunities still exist or has the window closed? What are the considerations in venturing into China and Asia? Join this Orrick and L.E.K. seminar to find out.